Inventiva’s fibrosis flop hits Nash hopes
A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.
Intercept’s big Nash day draws near
Intercept Pharmaceuticals and the whole Nash field await Ocaliva’s pivotal readout.
